152 related articles for article (PubMed ID: 38168573)
1. Benign prostatic hyperplasia - A novel autoimmune disease with a potential therapy consequence?
Liedtke V; Stöckle M; Junker K; Roggenbuck D
Autoimmun Rev; 2024 Mar; 23(3):103511. PubMed ID: 38168573
[TBL] [Abstract][Full Text] [Related]
2. Over-Expression of LEDGF/p75 in HEp-2 Cells Enhances Autoimmune IgG Response in Patients with Benign Prostatic Hyperplasia-A Novel Diagnostic Approach with Therapeutic Consequence?
Liedtke V; Rose L; Hiemann R; Nasser A; Rödiger S; Bonaventura A; Winkler L; Sowa M; Stöckle M; Schierack P; Junker K; Roggenbuck D
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047137
[TBL] [Abstract][Full Text] [Related]
3. Use of Tregs as a cell-based therapy via CD39 for benign prostate hyperplasia with inflammation.
Jin X; Lin T; Yang G; Cai H; Tang B; Liao X; Li H; Chen X; Gong L; Xu H; Sun Y; Tan P; Yin J; Ma H; Ai J; Wang K; Wei Q; Yang L; Li H
J Cell Mol Med; 2020 May; 24(9):5082-5096. PubMed ID: 32191396
[TBL] [Abstract][Full Text] [Related]
4. Transcriptomic analysis of benign prostatic hyperplasia identifies critical pathways in prostatic overgrowth and 5-alpha reductase inhibitor resistance.
Jin R; Forbes CM; Miller NL; Lafin J; Strand DW; Case T; Cates JM; Liu Q; Ramirez-Solano M; Mohler JL; Matusik RJ
Prostate; 2024 Apr; 84(5):441-459. PubMed ID: 38168866
[TBL] [Abstract][Full Text] [Related]
5. TNF is a potential therapeutic target to suppress prostatic inflammation and hyperplasia in autoimmune disease.
Vickman RE; Aaron-Brooks L; Zhang R; Lanman NA; Lapin B; Gil V; Greenberg M; Sasaki T; Cresswell GM; Broman MM; Paez JS; Petkewicz J; Talaty P; Helfand BT; Glaser AP; Wang CH; Franco OE; Ratliff TL; Nastiuk KL; Crawford SE; Hayward SW
Nat Commun; 2022 Apr; 13(1):2133. PubMed ID: 35440548
[TBL] [Abstract][Full Text] [Related]
6. Inflammatory Responses in a Benign Prostatic Hyperplasia Epithelial Cell Line (BPH-1) Infected with Trichomonas vaginalis.
Kim SS; Kim JH; Han IH; Ahn MH; Ryu JS
Korean J Parasitol; 2016 Apr; 54(2):123-32. PubMed ID: 27180569
[TBL] [Abstract][Full Text] [Related]
7. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease?
Kramer G; Mitteregger D; Marberger M
Eur Urol; 2007 May; 51(5):1202-16. PubMed ID: 17182170
[TBL] [Abstract][Full Text] [Related]
8. The prostaglandin pathway is activated in patients who fail medical therapy for benign prostatic hyperplasia with lower urinary tract symptoms.
Jin R; Strand DW; Forbes CM; Case T; Cates JMM; Liu Q; Ramirez-Solano M; Milne GL; Sanchez S; Wang ZY; Bjorling DE; Miller NL; Matusik RJ
Prostate; 2021 Sep; 81(13):944-955. PubMed ID: 34288015
[TBL] [Abstract][Full Text] [Related]
9. The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation.
De Nunzio C; Kramer G; Marberger M; Montironi R; Nelson W; Schröder F; Sciarra A; Tubaro A
Eur Urol; 2011 Jul; 60(1):106-17. PubMed ID: 21497433
[TBL] [Abstract][Full Text] [Related]
10. Omentin-1 inhibits the development of benign prostatic hyperplasia by attenuating local inflammation.
Wang YY; Zhu GQ; Xia K; Zeng HB; He YH; Xie H; Wang ZX; Xu R
Mol Med; 2024 Mar; 30(1):41. PubMed ID: 38519941
[TBL] [Abstract][Full Text] [Related]
11. Autoantibodies to prostate specific antigen in patients with benign prostatic hyperplasia.
Zisman A; Zisman E; Lindner A; Velikanov S; Siegel YI; Mozes E
J Urol; 1995 Sep; 154(3):1052-5. PubMed ID: 7543596
[TBL] [Abstract][Full Text] [Related]
12. Could inflammation be a key component in the progression of benign prostatic hyperplasia?
Kramer G; Marberger M
Curr Opin Urol; 2006 Jan; 16(1):25-9. PubMed ID: 16385197
[TBL] [Abstract][Full Text] [Related]
13. Correlation between benign prostatic hyperplasia and inflammation.
Bostanci Y; Kazzazi A; Momtahen S; Laze J; Djavan B
Curr Opin Urol; 2013 Jan; 23(1):5-10. PubMed ID: 23159991
[TBL] [Abstract][Full Text] [Related]
14. Seminal plasma cytokines and chemokines in prostate inflammation: interleukin 8 as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome and benign prostatic hyperplasia.
Penna G; Mondaini N; Amuchastegui S; Degli Innocenti S; Carini M; Giubilei G; Fibbi B; Colli E; Maggi M; Adorini L
Eur Urol; 2007 Feb; 51(2):524-33; discussion 533. PubMed ID: 16905241
[TBL] [Abstract][Full Text] [Related]
15. Traditional Chinese Medicine Danzhi qing'e decoction inhibits inflammation-associated prostatic hyperplasia via inactivation of ERK1/2 signal pathway.
Liu Y; Shao R; Suo T; Zhu J; Liu E; Wang Y; Miao L; Gao X
J Ethnopharmacol; 2023 Jun; 309():116354. PubMed ID: 36906158
[TBL] [Abstract][Full Text] [Related]
16. Chronic inflammation promotes proliferation in the prostatic stroma in rats with experimental autoimmune prostatitis: study for a novel method of inducing benign prostatic hyperplasia in a rat model.
Zhang M; Luo C; Cui K; Xiong T; Chen Z
World J Urol; 2020 Nov; 38(11):2933-2943. PubMed ID: 31965289
[TBL] [Abstract][Full Text] [Related]
17. Inhibitory Effect of Artemisinin on Testosterone Propionate Induced Benign Prostatic Hyperplasia.
Solanki A; Patel S; Solanki N; Shah U
Curr Drug Discov Technol; 2021; 18(4):518-524. PubMed ID: 32532194
[TBL] [Abstract][Full Text] [Related]
18. Could TNF-antagonists be a novel treatment strategy for BPH patients?
Vickman RE; Franco OE; Hayward SW
Cell Stress; 2022 Jun; 6(6):65-67. PubMed ID: 36072128
[TBL] [Abstract][Full Text] [Related]
19. Prostatic Artery Embolization (PAE) for Symptomatic Benign Prostatic Hyperplasia (BPH): Part 1, Pathological Background and Clinical Implications.
Sun F; Crisóstomo V; Báez-Díaz C; Sánchez FM
Cardiovasc Intervent Radiol; 2016 Jan; 39(1):1-7. PubMed ID: 26581418
[TBL] [Abstract][Full Text] [Related]
20. Microwave thermotherapy for benign prostatic hyperplasia.
Hoffman RM; Monga M; Elliott SP; Macdonald R; Langsjoen J; Tacklind J; Wilt TJ
Cochrane Database Syst Rev; 2012 Sep; (9):CD004135. PubMed ID: 22972068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
